Collegium Pharmaceutical (NASDAQ:COLL) Rating Reiterated by Piper Sandler

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “neutral” rating restated by Piper Sandler in a report issued on Friday, Benzinga reports. They currently have a $37.00 price target on the specialty pharmaceutical company’s stock. Piper Sandler’s target price points to a potential downside of 1.91% from the company’s previous close.

Several other research analysts also recently issued reports on COLL. Truist Financial upped their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. HC Wainwright lifted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Trading Up 2.9 %

Shares of NASDAQ COLL opened at $37.72 on Friday. The stock has a market cap of $1.21 billion, a P/E ratio of 14.62 and a beta of 0.94. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. Collegium Pharmaceutical has a 1 year low of $20.95 and a 1 year high of $42.29. The firm has a 50-day moving average of $37.27 and a 200 day moving average of $35.48.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. The firm had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.13 earnings per share. As a group, sell-side analysts expect that Collegium Pharmaceutical will post 5.79 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Pacer Advisors Inc. increased its holdings in Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after acquiring an additional 821,541 shares in the last quarter. Rubric Capital Management LP raised its position in shares of Collegium Pharmaceutical by 27.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares during the period. Vanguard Group Inc. lifted its stake in shares of Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after buying an additional 17,942 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Collegium Pharmaceutical by 8.2% in the 2nd quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock worth $54,124,000 after buying an additional 128,003 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Collegium Pharmaceutical by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.